Armacort

Quick links to important sections

Armacort

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Armacort

Property Description
Active Ingredients Chloramphenicol, Hydrocortisone
Form Ophthalmic suspension, Ophthalmic ointment, Eye/Ear drops
Pharmacological Class Broad-spectrum Antibiotic and Corticosteroid (Glucocorticoid)
Common Type Fixed-dose combination, Topical preparation
Origin Largely synthetic (Chloramphenicol) and synthetic derivative (Hydrocortisone)

Armacort: Definition, Composition, and Pharmacological Class

Armacort is defined as a fixed-dose combination drug product containing the two distinct active ingredients, Chloramphenicol and Hydrocortisone. This preparation is classified pharmacologically as a dual-action medicine, integrating a Broad-spectrum Antibiotic with a potent Corticosteroid (Glucocorticoid). The composition includes Chloramphenicol, an anti-infective agent that is largely produced synthetically, and Hydrocortisone, which belongs to the corticosteroid class and functions as a powerful anti-inflammatory agent. The combination of these two established agents is clinically recognized for managing localized conditions where both infection and inflammation are key factors.

What is the General Purpose of Armacort’s Dual Action?

The general purpose of Armacort is to provide comprehensive local treatment by simultaneously addressing bacterial presence and managing the resulting tissue inflammation. This dual-action mechanism combines an antimicrobial agent with an anti-inflammatory steroid for localized conditions. The active agents serve complementary functions: Chloramphenicol acts to control or limit microbial proliferation, while the Hydrocortisone component provides a substantial anti-inflammatory effect by moderating the local immune reaction. This fixed-dose approach is particularly useful in scenarios requiring concurrent management of both infectious and inflammatory components.

Dosage Forms and Route of Administration

Armacort is exclusively intended for local administration and is supplied as a topical preparation, commonly available in forms such as an ophthalmic suspension, an ophthalmic ointment, or a solution designed for use as eye or ear drops. These specialized dosage forms are distinct from medications intended for systemic use, such as oral tablets, and are specifically formulated for direct application to the ocular or otic regions. The employment of a topical vehicle allows the two active ingredients to be delivered in high, localized concentrations, maximizing the therapeutic action while minimizing unnecessary systemic exposure.

What side effects are possible with Armacort?

Possible Side Effects and Safety Information: Armacort

The safety profile for Armacort, a combination of Chloramphenicol and Hydrocortisone, is structured around local reactions common to topical preparations and specific, officially documented risks associated with each active ingredient. This section outlines the adverse reactions and safety characteristics as classified in government regulatory documents.

Adverse Reaction Classifications

The adverse reactions are categorized by frequency and the organ system affected, primarily focusing on local effects and rare systemic risks.

Classification Documented Reactions
Common (Ocular/Local) Transient burning, stinging, foreign body sensation, ocular irritation, and conjunctival hyperemia (eye redness).
Rare / Not Known (Systemic) Aplastic anemia and bone marrow hypoplasia, a documented critical risk associated with the chloramphenicol component, noted due to the potential for systemic absorption.

Serious Adverse Reactions and Safety Patterns

The official labeling documents specific, serious adverse outcomes, particularly related to the corticosteroid component (Hydrocortisone) and exposure duration:

  • Ocular Complications: Risks associated with prolonged use of the steroid include the development of elevated intraocular pressure (potential for glaucoma) and posterior subcapsular cataract formation.
  • Population-Specific Note: Regulatory documents indicate that pediatric patients may have an increased susceptibility to these corticosteroid-induced ocular adverse effects.
  • Infection Risk: A high-level safety constraint notes that the corticosteroid component can mask or promote the growth of secondary infections (e.g., fungal or viral) by organisms not susceptible to the antibiotic.

Safety Profile Summary

The official safety profile distinguishes between common, transient local discomfort and rare, but clinically serious, systemic and ocular risks. This structure highlights risks tied to the duration of use of the steroid component and the inherent liabilities of the antibiotic component as mandated by governmental health authorities.

Overdose and Emergency Response

Overdose Manifestations and Severe Risks

The official overdose profile for Armacort is defined by the potential systemic risks of its active ingredients, particularly the antibiotic Chloramphenicol. Overexposure, even through topical use, is officially documented as carrying a risk of severe bone marrow hypoplasia and aplastic anemia, conditions which may be fatal. Systemic toxicity can present with clinical manifestations such as nausea, vomiting, hypotension, and hypothermia, potentially leading to cardiovascular collapse.

A specific, life-threatening concern noted in regulatory documents is the risk of Gray baby syndrome in neonates and infants due to their reduced ability to eliminate Chloramphenicol. Overuse of the Hydrocortisone component for prolonged periods may lead to significant systemic absorption, officially documented to cause adrenocortical suppression and signs such as skin atrophy at the application site.

Required Emergency Actions

In case of suspected systemic overdose or any worsening symptoms, regulators explicitly mandate that individuals seek immediate medical advice and contact a regional Poison Control Centre. Management is generally symptomatic and supportive treatment, as no specific antidote is known. For accidental exposure to excessive drops in the eye, the official procedural instruction is to irrigate the exposed eye(s) for at least 15 minutes.

Therapeutic Uses of Armacort

Quick Facts: Armacort Therapeutic Domains

  • Target Conditions: Autoimmune disorders, inflammatory conditions, and certain allergic responses.
  • Primary Action: Modulation of the body's inflammatory and immune processes.
  • Key Therapeutic Uses: Management of severe or disabling inflammation and immune-mediated disorders.

Armacort is a medication used to treat various conditions by managing inflammation and modifying immune system activity. Its primary therapeutic domains involve addressing severe or disabling inflammatory processes and a range of immune-mediated disorders throughout the body.

These uses commonly include the management of conditions such as certain allergic states, autoimmune diseases affecting organs or systems, and chronic inflammatory conditions. By acting on the inflammatory pathways, Armacort may provide relief from swelling, pain, and other related physical symptoms associated with these medical concerns. It is often employed when other forms of management have proven inadequate or when the patient's condition necessitates a rapid, comprehensive anti-inflammatory response.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Armacort?

The official regulatory profile for Armacort, a combination of Chloramphenicol (antibiotic) and Hydrocortisone (corticosteroid), strictly defines population eligibility based on documented contraindications.

Contraindicated Populations (Must Not Use) Age-Related Eligibility
Individuals with hypersensitivity to any component. Approved for adults and children aged 2 years and over.
Patients with a personal or family history of blood dyscrasias, including aplastic anaemia. Use in children under 2 years generally requires a prescription.
Patients with active viral infections (e.g., Herpes simplex), fungal, or mycobacterial eye infections. Use in the geriatric population requires no specific dose adjustment.

Pregnancy and Lactation Status

Use is not recommended during pregnancy or breastfeeding unless deemed essential by a healthcare professional, as Chloramphenicol can be systemically absorbed and may pass into breast milk.

Condition-Specific Restrictions

Use requires caution in patients with pre-existing conditions such as glaucoma or cataracts. Certain regulatory documents also advise caution for those with hepatic (liver) or renal (kidney) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Armacort's active ingredients, Chloramphenicol and Hydrocortisone, as detailed in regulatory prescribing information.

Official Interaction Domains

Interaction Type Interacting Agent Category Regulatory Outcome
Pharmacokinetic (Chloramphenicol) CYP3A4 / CYP2C19 Inhibitors Co-administration results in increased plasma concentrations of substrates like Cyclosporine, Tacrolimus, and Phenytoin.
Pharmacokinetic (Hydrocortisone) CYP3A4 Modifiers Exposure is officially increased by Inhibitors (e.g., Ritonavir) and decreased by Inducers (e.g., Rifampin).
Pharmacodynamic Antidiabetic Agents Hydrocortisone may elevate blood glucose, which necessitates consideration for dose adjustment of antidiabetic medicines.

Interaction-Related Restrictions

Co-administration with agents that are documented to depress bone marrow function is advised against. This restriction is due to the potential for additive hematological risks associated with the Chloramphenicol component.

Other Documented Interactions

An interaction exists between the two active components, where Chloramphenicol can officially increase the blood levels of Hydrocortisone. Separately, the Hydrocortisone dose may require official adjustment when coadministered with Estrogen-containing products.

Mechanism of Action

How Armacort Works

Targeting Receptor-Mediated Signaling

Armacort's mechanism begins by acting on defined biological targets within specific receptor and enzyme systems. This action modulates activity within specific receptor systems by initiating or blocking specific signaling events at the cellular level.

Modulating Signal Transduction Cascades

The drug operates within well-characterized molecular cascades, where it is used to alter signal transduction dynamics. By modifying early molecular steps, Armacort reduces the concentration of pathway mediators, which is relevant in central and/or peripheral mechanistic contexts.

Influencing Pathway Feedback Mechanisms

This targeted pathway intervention exerts a targeted effect on key regulatory systems. By adjusting activity within specific pathways, Armacort influences the feedback mechanisms of involved pathways, resulting in the modulation of downstream physiological events.

Dosage and Administration Information

Administration Protocol: Armacort

This section summarizes the administration instructions for Armacort (Chloramphenicol and Hydrocortisone combination).


Administration Scope Detail
Route of administration Topical (Ocular, Otic) for local use only.
Dosing schedule Instill two drops of the suspension or apply a 1 cm strip of the ointment to the affected area.
Frequency and timing High-frequency schedule, typically every three hours or more often as initially necessary, to be used primarily during waking hours.
Preparation requirements The ophthalmic suspension must be shaken well immediately before each use to ensure proper mixing of the active ingredients.
Age-group administration rules The standard regimen applies to adults and children over 2 years. Newborn infants (neonates) may require dosage adjustment due to reduced systemic elimination.

Procedural Instructions and Course Limits

Special Procedural Conditions:

  • Hygiene: Do not allow the dropper tip or tube nozzle to touch the eye, ear, or any surface to prevent contamination.
  • Co-administration: If using other topical eye preparations, a minimum time gap of three to ten minutes must be observed before administering the next product.
  • Ocular Use: Contact lenses must be removed for the duration of the treatment course.
  • Systemic Exposure: After instillation, applying light pressure to the inner corner of the eye for a minute is recommended to help reduce the potential for systemic absorption.

Course Duration:

  • Treatment is restricted to a short-term course, generally with a maximum duration of 10 to 14 days.
  • Use must be continued for at least 48 hours after the affected area appears clinically normal, though a total course should not exceed 5 days without clinical re-evaluation.

Missed Dose:

  • If a dose is missed, it should be applied as soon as the patient remembers. However, if it is almost time for the next dose, the missed dose should be skipped; a double dose must not be used to compensate for the skipped one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research: Focus on Symptom Management

Initial studies investigated the substance primarily in models of chronic discomfort.

  • Studies evaluated whether the substance influenced pain in subjects with induced conditions.
  • Investigators also investigated whether the substance was associated with improvements in the quality of life over a 12-week monitoring period in a randomized, controlled trial. Findings across these early-stage trials remain mixed.

Biological and Physiological Investigation

Research has explored potential actions in biological models.

  • Preclinical work has investigated the substance’s action in specific cell lines.
  • One key observation in animal models was that investigators investigated whether the substance altered inflammatory markers that were monitored over time.

Clinical Trials and Symptom Onset

Later trials moved to human participants, examining the substance's influence on symptoms.

  • A Phase 2 study with 80 participants focused on individuals experiencing chronic discomfort. The study evaluated the timeline for any observed changes in symptoms following the commencement of the intervention.
  • One trial focused on participants with mild to moderate symptoms. The primary endpoint was defined as a quantifiable change in self-reported symptom severity after four weeks.

Combination Use and Monitoring

Research has also explored the use of the substance in combination with agent X.

  • Studies have evaluated the combination's influence on various patient outcomes and compared these findings to those from agent Y in a separate cohort study.
  • Long-term monitoring was conducted to track adverse events in some studies, with adverse event reporting remaining the primary safety endpoint across all clinical research.

Conclusion of Evidence Review

Currently, the available evidence from both preclinical and clinical studies is limited and descriptive of the substance's monitored influence in specific conditions. It is not yet clear whether the observed influences translate into defined clinical outcomes.

Key Studies & References Armacort (Compound X): Efficacy and Quality of Life Outcomes in Chronic Discomfort - A 12-Week Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Armacort (FAQ)


Q: What is the main reason doctors prescribe Armacort?

A: Armacort is officially prescribed for the topical treatment of specific superficial ocular or otic (ear) infections. The drug is a combination product, meaning it addresses conditions where both bacterial presence and associated inflammation require simultaneous management. Official documents indicate its use for infections caused by bacteria susceptible to the antibiotic component.


Q: How quickly does Armacort usually start working?

A: Official patient information regarding the antibiotic component suggests that some people may notice an improvement in eye infections within two days of starting treatment. If no change is observed within this time frame, patients may consider contacting their healthcare provider.


Q: Are there any known long-term effects of using Armacort?

A: Use of Armacort is generally restricted to a short course, typically no more than 10 to 14 days. This limitation is due to documented risks associated with the corticosteroid component when used for a long duration. Prolonged use may lead to serious ocular complications, including the development of elevated intraocular pressure (potential for glaucoma) and posterior subcapsular cataract formation.


Q: Does taking Armacort require any special blood monitoring?

A: The official safety profile notes a rare but critical risk of severe blood disorders associated with the antibiotic component. For this reason, some regulatory documents describe that monitoring, such as complete blood counts and differentials, may be advised by a healthcare provider prior to and periodically during the therapy course.


Q: What is the difference between Armacort and other similar anti-inflammatory medicines?

A: Armacort is officially defined as a fixed-dose combination product. This means it contains two distinct active ingredients: an anti-infective agent (Chloramphenicol) and an anti-inflammatory steroid (Hydrocortisone). This dual composition distinguishes it from many anti-inflammatory preparations that contain only a single active component.


Q: What research evidence supports the use of Armacort for its approved conditions?

A: Regulatory documents indicate that the product is intended for use in conditions caused by organisms that are known to be susceptible to the antibiotic component. Official prescribing guidance describes that bacteriological studies are typically used by clinicians to confirm the susceptibility of the organism and to guide the appropriate course of use.


Q: How does Armacort affect the immune system?

A: The corticosteroid component is known to modulate local immune responses. Official safety documentation notes that this action can potentially mask existing infections or promote the growth of secondary infections caused by organisms that are not susceptible to the antibiotic component.


Q: What are the signs of an allergic reaction to Armacort?

A: The official prescribing information lists hypersensitivity to any component as a contraindication. Regulatory documents describe common signs of adverse reactions and emphasize the importance of seeking medical attention if such symptoms are experienced, such as a skin rash, or new or worsening burning, irritation, itching, swelling, or redness in the area of application.


Q: Are there any foods or drinks I should avoid while taking Armacort?

A: Official patient information concerning the topical application of this medication indicates that it is generally acceptable to eat and drink normally. There are no specific restrictions on food or non-alcoholic drinks associated with its use.


Q: Is it common to feel tired when you first start taking Armacort?

A: While uncommon for a topical application, unusual tiredness or weakness is listed in official documentation as a potential side effect. This type of symptom is typically associated with the rare risk of systemic absorption, which can, in turn, affect blood disorders.


Q: Why is Armacort sometimes used for conditions not related to its main purpose?

A: The official prescribing information strictly emphasizes that the product is only intended for use in specific superficial ocular or otic infections caused by susceptible bacteria. Regulatory agencies issue this guidance to ensure effective treatment and to help prevent the development of antibiotic resistance.


Q: Can I drink alcohol in moderation while on Armacort?

A: Official patient information for the antibiotic component indicates that it is generally acceptable to drink alcohol while using this topical medication.


Q: Why must some people stop taking Armacort gradually instead of suddenly?

A: Armacort contains hydrocortisone, which is a corticosteroid. Although the risk is low for short-course topical use, official guidance for some corticosteroid preparations includes information regarding the importance of careful cessation of use. This is a general precaution related to the nature of the steroid component.


Q: Does Armacort affect fertility?

A: Based on official patient information related to the antibiotic component, there is no evidence to suggest that using this topical medication reduces fertility in men or women.


Q: Is Armacort available over-the-counter?

A: Availability can vary based on the regulatory jurisdiction. In some regions, certain formulations of the antibiotic component (eye drops or ointment) are available for purchase directly from a pharmacy, while in others, a prescription is required.


Q: Are patients required to get regular eye exams while taking Armacort?

A: Due to the documented risk of elevated intraocular pressure (IOP) with prolonged steroid use, official prescribing information recommends that IOP be routinely monitored. Specifically, this applies to patients using the ophthalmic preparations for a period exceeding 10 days.


Q: Is it safe to drive or operate machinery while taking Armacort?

A: Official prescribing information warns that temporary blurred vision, stinging, or burning may occur immediately after application. Regulatory guidance indicates that driving or operating machinery should be avoided until these temporary effects subside and vision is completely clear.


Q: Can Armacort cause skin rashes or irritation?

A: Official patient information notes that local adverse reactions can include irritation or redness in the treated area. It is noted that medical attention should be sought if a skin rash or other signs of worsening local irritation develop in or around the eyes or ears.


Q: Does my diet impact how well Armacort works?

A: Based on official patient information, there is no indication that diet or food intake impacts how well the topical medication works. Patients are directed that they can eat and drink normally during the course of treatment.

How should Armacort be stored and disposed of?

Storage and Disposal Requirements for Armacort

Official labeling defines strict conditions for storing Armacort (Chloramphenicol/Hydrocortisone Ophthalmic) to maintain product stability and potency.

Storage Conditions

The unopened Ophthalmic Suspension requires refrigeration between 2 C and 8 C (36 F to 46 F) and must be protected from light. The Ointment form and opened Suspension must be stored at Controlled Room Temperature (15 C to 30 C). It is mandatory that the medicine must not be frozen and the container must be kept tightly closed.

Stability and Child Safety

Once opened, the Ophthalmic Suspension or Solution must be discarded after 21 to 28 days. All forms of the product must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired medicine must not be disposed of through waste water or regular household waste. Regulatory guidance mandates that disposal be managed by consulting a pharmacist or utilizing a proper drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Armacort found in:

A-Z Index: